DELCATH SYSTEMS, INC. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>DELCATH SYSTEMS, INC. has filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing its financial performance and operational status.</b>

AI Summary

DELCATH SYSTEMS, INC. (DCTH) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. DELCATH SYSTEMS, INC. filed a 10-Q report for the period ending March 31, 2024. The filing covers the first quarter of fiscal year 2024. The company's principal executive offices are located in Queensbury, NY. The standard industrial classification for the company is Surgical & Medical Instruments & Apparatus. The filing was submitted on May 14, 2024.

Why It Matters

For investors and stakeholders tracking DELCATH SYSTEMS, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest financial data and operational updates for DELCATH SYSTEMS, INC. for the first quarter of 2024, enabling informed investment decisions. Understanding the details within this report is crucial for assessing the company's current financial health, strategic direction, and potential risks and opportunities in the medical instruments sector.

Risk Assessment

Risk Level: low — DELCATH SYSTEMS, INC. shows low risk based on this filing. The filing is a standard 10-Q report, which typically contains routine financial and operational information, posing no immediate or unusual risks.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand DELCATH SYSTEMS, INC.'s performance in Q1 2024.

Key Numbers

• 2024-03-31 — Period End Date (Conformed Period of Report)
• 2024-05-14 — Filing Date (Filed as of Date)
• 0000872912 — Central Index Key (Filer's Central Index Key)
• 3841 — SIC Code (Standard Industrial Classification)

Key Players & Entities

• DELCATH SYSTEMS, INC. (company) — Filer name
• 0001628280-24-023087 (filing_id) — Accession Number
• 20240331 (date) — Period of Report
• 20240514 (date) — Filing Date
• Queensbury, NY (location) — Business Address
• 3841 (industry_code) — Standard Industrial Classification
• 001-16133 (filing_id) — SEC File Number

FAQ

Industry Context

DELCATH SYSTEMS, INC. operates within the Surgical & Medical Instruments & Apparatus industry.

Regulatory Implications

The company is subject to standard SEC reporting requirements for public companies, including the filing of 10-Q quarterly reports.

What Investors Should Do

1. Analyze the financial statements for revenue, net income, and cash flow for Q1 2024.
2. Review any disclosures regarding new products, regulatory approvals, or market strategies.
3. Assess the company's liquidity and debt position as presented in the balance sheet.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-14: Filing Date — Date the 10-Q report was officially filed with the SEC.

Year-Over-Year Comparison

This is the 10-Q filing for the first quarter of 2024, providing updated financial and operational information compared to previous filings.

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value per share DCTH The Nasdaq Cap
• $0.1 million — d March 31, 2024 and 2023 was less than $0.1 million for each period. 11 Table of Content

Filing Documents

• dcth-20240331.htm (10-Q) — 889KB
• dcth-20240331xexx311.htm (EX-31.1) — 10KB
• dcth-20240331xexx312.htm (EX-31.2) — 10KB
• dcth-20240331xexx321.htm (EX-32.1) — 5KB
• dcth-20240331xexx322.htm (EX-32.2) — 5KB
• 0001628280-24-023087.txt (&nbsp;) — 6752KB
• dcth-20240331.xsd (EX-101.SCH) — 67KB
• dcth-20240331_cal.xml (EX-101.CAL) — 74KB
• dcth-20240331_def.xml (EX-101.DEF) — 275KB
• dcth-20240331_lab.xml (EX-101.LAB) — 657KB
• dcth-20240331_pre.xml (EX-101.PRE) — 469KB
• dcth-20240331_htm.xml (XML) — 938KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 3 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 4 Unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three ended March 31, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 6 Notes to the Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 28

—OTHER INFORMATION

PART II—OTHER INFORMATION 29 Item 1 .

Legal Proceedings

Legal Proceedings 29 Item 1A.

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 29

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 29

Other Information

Item 5. Other Information 29 Item 6. Exhibits 30

SIGNATURES

SIGNATURES 31 2 Table of Contents DELCATH SYSTEMS, INC. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share data) March 31, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 11,760 $ 12,646 Restricted cash 50 50 Short-term investments 15,360 19,808 Accounts receivable, net 1,564 241 Inventory 3,634 3,322 Prepaid expenses and other current assets 1,278 1,091 Total current assets 33,646 37,158 Property, plant and equipment, net 1,336 1,352 Right-of-use assets 1,117 103 Total assets $ 36,099 $ 38,613 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,487 $ 1,012 Accrued expenses 4,395 5,249 Lease liabilities, current 102 37 Loan payable 2,408 5,239 Convertible notes payable 4,949 4,911 Total current liabilities 13,341 16,448 Warrant liability 6,160 5,548 Lease Liabilities, non-current 1,016 — Other liabilities, non-current 962 840 Total liabilities 21,479 22,836 Commitments and contingencies (see Note 15) Stockholders' equity Preferred stock, $ 0.01 par value; 10,000,000 shares authorized; 16,809 and 24,819 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 25,439,319 shares and 22,761,554 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 254 228 Additional paid-in capital 530,482 520,576 Accumulated deficit ( 516,273 ) ( 505,162 ) Accumulated other comprehensive loss 157 135 Total stockholders' equity 14,620 15,777 Total liabilities and stockholders' equity $ 36,099 $ 38,613 See accompanying Notes to Condensed Consolidated Financial Statements. 3 Table of Contents DELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three months ended March 31, 2024 2023 Product revenue $ 3,139 $ 597 Other

View Full Filing

View this 10-Q filing on SEC EDGAR